Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2018 16:35 ET | Source: IMV Inc.

IMV Leadership to Present Respiratory Syncytial Virus (RSV) Research at RespiDART 2018

DARTMOUTH, Nova Scotia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will present data on its DPX-RSV...
November 20, 2018 07:05 ET | Source: IMV Inc.

IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer

DARTMOUTH, Nova Scotia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced an amendment to its phase 1b/2 clinical...
November 15, 2018 07:05 ET | Source: IMV Inc.

IMV Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference

DARTMOUTH, Nova Scotia, Nov. 15, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors...
November 06, 2018 07:05 ET | Source: IMV Inc.

Veteran Oncology Biotechnology Executive and Third Rock Ventures Entrepreneur in Residence Markus Warmuth, MD, Joins IMV Inc. Board of Directors

DARTMOUTH, Nova Scotia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has appointed seasoned...
November 02, 2018 07:05 ET | Source: IMV Inc.

IMV Inc. Announces Q3 2018 Financial Results and Investor Conference Call Details

Achieved Initial Positive Data from Phase 2 Clinical Trial in DLBCL with MerckEntered into Collaboration with Merck on Phase 2 Basket Trial Across Five IndicationsAttained Multiple Milestones in...
October 23, 2018 07:05 ET | Source: IMV Inc.

IMV Inc. to Announce Third Quarter 2018 Financial Results and Host Earnings Call on November 2, 2018

DARTMOUTH, Nova Scotia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a...
October 09, 2018 07:05 ET | Source: IMV Inc.

IMV Inc. to Present at Upcoming Investor Conferences

DARTMOUTH, Nova Scotia, Oct. 09, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors...
September 27, 2018 07:05 ET | Source: IMV Inc.

IMV Provides Update on Progress of its DPX-RSV Program

DARTMOUTH, Nova Scotia, Sept. 27, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced results of ongoing research to further...
September 18, 2018 07:05 ET | Source: IMV Inc.

IMV Inc. Announces Early Positive Results from Phase 2 Clinical Trial of Lead Candidate DPX-Survivac in Combination with Merck’s Keytruda® in Patients with DLBCL

DARTMOUTH, Nova Scotia, Sept. 18, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced details of the initial data from an ongoing...
September 11, 2018 07:05 ET | Source: IMV Inc.

IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications

HALIFAX, Nova Scotia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program...